Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
UBS is the top ranked Bank for M&A (average deal over $2bil)
UBS leads GlobalData’s top 10 global M&A financial advisers league table across Asia-Pacific in 2019
Posted in Business Fundamentals
UBS has dominated the latest mergers and acquisitions (M&A) league table of the top 10 financial advisers in Asia-Pacific based on deal value in 2019, according to GlobalData, a leading data and analytics company.
The Swiss investment bank advised on 42 deals worth US$83.2bn.
According to GlobalData, which tracks all M&A, private equity/venture capital and asset transaction activity around the world to compile the league tables, Morgan Stanley ranked second with 51 deals worth US$58.5bn.
Must Watch interview. Exciting future. How did we lose 18% on this interview. Crazy....main market and with a Market Cap of less than £2million.
Nice pun...Nulupus.
Can we not vote to sack Tim?
NOT a happy chippy today...in fact quite annoyed! Incanthera today starts trading on Nex. Tim McCarthy’s has cost us dearly. Our 2 millionaire pounds investment in Incanthera is today worth £690 913
Gulagescapee. I believe you are incorrect on Day Trading within an ISA. I believe its TAX Free.
90% of DAY Traders lose ALL their money. -
In a normal trading Account...Loses can be carried forward to offset agains future gains.
Looking for 5p before I sell any. Thats a 20M Market Cap. A nice Oil & Gas deal will propel the share price to this level at least! DYOR
I will topslice at 5p! that's will MNRG at a Market Cap of 10M peanuts!!!! for a full LSE listing!
Even a SMALL O & G deal this month could easily propel MNRG to a market cap of 10M - 15M that 4 - 5 pence a share ...this company Market Cap is so tiny....1.58 Million....or a 9 bagger from here. Possible the smallest Market Cap on the London's Main listings!
No, I don't think so. Best not play with T+ Trades...Just in case of suspension.
Just a note of caution for those trading in and out of EUA. If a bid come in for EUA, the price will GAP UP Instantly!
NO Buying or selling will be possible.
The MM will move the price to approx 95% of the Offer Value. If the market believes a counter offer is possible, the price will rise above the Offer!
You have to be in it to Win it!
Companies try to do it on the cheap, drilling on only 2D or a combination of 2D/3D. Bad interpretation of that data leads to dry holes.
88E in the past have, imo, done things on the cheapy cheap and paid the penalty for it.
This time they are using 3D inversion as well. They are combining old well data, with 2D and 3D and doing inversion. 3D inversion helps select the best possible place to drill in terms of good reservoir characteristics.
The whole point was - the data has been checked by 88E and their consultants, its been reworked by PMO - they are doing 3D Inversion as well using a modern 3D seismic.
This means that this time, unlike the last few times, the chances of success in terms of hitting the right bit of the reservoir in the primary targets is good. Never 100%, but its very good. (Also the Indigo target looks quite interesting, but for me I am writing it off and allowing it to be good news upside not expected in the case its good).
I really dont know how core samples come into the 3D Inversion and seismic mapping - but anyway - glad you found the discussion interesting.
I should keep to that famous quote:
Great minds discuss ideas;
Average minds discuss events;
Small minds discuss people
Nolupus...Funny how 2 weeks ago your words " if you were a betting man" you would have bought IMM...How do you explain the negativity...You exited your trade too early????
No credibility in anything you post!
Bermuda....good post. Totally agree
To the other poster that mentioned the Gap up...Yep..gap up. Gaps don’t necessarily get filled on transformation company news.
Funding....Sorted for the next 2 years...check previous RNS.s
Yep...just added 30k worth too
Motif Bio (MTFB) 37.55p Antibiotics developer Motif Bio (MTFB) is reaching an important point in the development of its new antibiotic Iclaprim, which is focused on acute bacterial skin and skin structure infections (ABSSSI). Antibiotic resistance is a key topic in the healthcare sector so new antibiotics are essential. Iclaprim was originally discovered by Hoffman-La Roche, but Motif has adapted the development programme to address the reasons it failed to gain FDA approval in 2009. Iclaprim has shown that it is at least as good as existing antibiotics in treating skin infections, but without the side effects of the rivals. It can be used on very sick patients. The plan is to lodge a new drug application in the US during the first quarter of 2018. If things go smoothly, then there could be a commercial treatment by the end of 2018. Motif has secured a $20 million loan facility, which more than doubled the available cash. A shelf registration in the US will enable Motif, which is also listed on Nasdaq, to raise up to $80m over a three-year period, although it says that no fundraising is currently planned. The US hospital market will be targeted via a contract sales organisation, while in Europe a partner will be sought and they will provide milestone payments to help to finance the approvals process in the region. Moving towards approvals that confirm that Iclaprim is a commercial product should propel the share price upwards.
MTFB 36p on AIM....equivalent 40p Finish on Nasdaq....
It�s quiet as we private investors are selling and Merrill Lynch a huge institutional are buying and increasing their holding. See recent holding RNS.... Mtfb should be worth �300 million right now.
With FDA approval...this will be taken over for 3-4billion pounds in 2018
The market will soon retrate Motif like it has with a similar situation in Immupharma t� FDA approval and future revenues. This will be 70p by year end if it follows Imm rerate.
Yes...30p is a support level on the charts